Concord Biotech
- Market cap
- ₹ 12,927 Cr.
- P/E
- 46.6x
- P/B
- 6.58x
- 52-week range
- 987 – 1,615
- ROE
- 13%
- ROCE
- 17%
- Dividend yield
- 0.6%
- Debt / equity
- 0
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
About
Concord Biotech Limited is an India-based research and development-driven biopharmaceutical company focused on manufacturing fermentation-based active pharmaceutical ingredients (APIs) and formulations. The Company is engaged in research and development, manufacturing, marketing and selling of pharmaceutical products. Its product portfolio encompasses both biopharmaceutical APIs and formulations across various therapeutic areas, including immunosuppressants, oncology, anti-infectives, nephrology, and critical care. Its API products include Immunosuppressant, Oncology Drugs, Anti-bacterial, and others. Its Immunosuppressant include Tacrolimus, Mycophenolate Mofetil, Mycophenolate Sodium, Cyclosporine, Sirolimus, Pimecrolimus, and Voclosporin. Its Oncology Drugs include Temsirolimus, Everolimus, Romidepsin, Mitomycin, Dactinomycin, Midostaurin, and Doxorubicin. Its Anti-bacterial include Mupirocin, Mupirocin Calcium, Teicoplanin, and others.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Concord Biotech against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)46.6 against a typical 34.3: pricier than most peers (1st = cheapest).150th of 220
- Sales growth+27.9% against a typical +15.6% from a year earlier.61st of 197
- Profit growth+41.9% against a typical +18.9% from a year earlier.60th of 160
- Share price, 3 months−4.9% against a typical −0.5%.123rd of 200
- Size₹ 12,926.9 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).37th of 199
Latest announcements
Exchange filings and their impact on the company.
- Strong Q2 with 25% revenue growth puts FY27 on track for ~22% sales and ~17% profit growth despite softer margins.
Concord Biotech reported Q2 FY27 consolidated revenue of Rs 309.1 cr, up 25% from Rs 247.1 cr a year ago, and net profit of Rs 69.6 cr, up 10%. For the first half, revenue grew 26% to Rs 566.6 cr and profit grew 19% to Rs 127.3 cr. The board also fixed November 4, 2026 as the record date for its 1:1 bonus issue and reconstituted board committees.
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
High safety
Rated AA- by ICRA- No warnings from the agency.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| ICRA | [ICRA]AA- | Stable | 23 Sep 2026 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 23 Sep 2026 | Reaffirmed | [ICRA]AA- | — | ICRA | ₹ 125 Cr. |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 27 Oct 2026 | Financial Results | To consider and approve the financial results for the period ended September 30, 2026 |
| 23 Sep 2026 | Bonus | To consider bonus |
| 31 Jul 2026 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2026 |
| 29 May 2026 | Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2026 and dividend |
| 11 Feb 2026 | Financial Results | To consider and approve the financial results for the period ended December 31, 2025 |
| 13 Nov 2025 | Financial Results | To consider and approve the financial results for the period ended September 30, 2025 |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 262 | 241 | 319 | 216 | 310 | 244 | 430 | 204 | 247 | 278 | 326 | 261 |
| Expenses | 143 | 135 | 185 | 135 | 174 | 146 | 239 | 143 | 157 | 176 | 204 | 173 |
| Operating Profit | 119 | 106 | 134 | 81 | 137 | 98 | 190 | 61 | 91 | 102 | 122 | 87 |
| OPM % | 45% | 44% | 42% | 38% | 44% | 40% | 44% | 30% | 37% | 37% | 38% | 33% |
| Other Income | 8 | 8 | 11 | 10 | 10 | 15 | 9 | 14 | 13 | 7 | 16 | 13 |
| Interest | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 13 | 14 | 14 | 13 | 13 | 13 | 15 | 18 | 18 | 19 | 19 | 18 |
| Profit before tax | 113 | 100 | 131 | 78 | 133 | 99 | 185 | 57 | 86 | 90 | 118 | 82 |
| Tax % | 25% | 26% | 26% | 25% | 26% | 25% | 23% | 26% | 26% | 25% | 24% | 26% |
| Net Profit | 84 | 75 | 97 | 58 | 99 | 74 | 142 | 43 | 63 | 68 | 90 | 61 |
| EPS in Rs | 8.08 | 7.13 | 9.29 | 5.57 | 9.43 | 7.08 | 13.57 | 4.07 | 6.01 | 6.48 | 8.6 | 5.85 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 14%
- 5 Years
- 11%
- 3 Years
- 7%
- TTM
- −6%
- 10 Years
- 11%
- 5 Years
- 1%
- 3 Years
- 1%
- TTM
- −20%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- 19%
- TTM
- —
- 10 Years
- —
- 5 Years
- 18%
- 3 Years
- 18%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Concord Biotech | ₹ 1,265.60 | ₹ 12,927 Cr. | 46.6x | 6.6x | 13% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Sudhir Kumar Vaid
- Executive Chairman of the Board, Managing Director
- Ankur Vaid
- Chief Executive Officer, Joint Managing Director, Executive Director
- Raviraj Karia
- Chief Financial Officer
- Paritosh Trivedi
- Compliance Officer, Company Secretary
- Devang Bhatt
- Vice President - Sales and Marketing, Head - Limbasi Plant - 3
- Manoj Kumar
- Vice-President - Formulation Division and Head - Valthera Unit - 2
- Sundeep Bengani
- General Manager - International Business Development, Formulation Division
Prices are delayed and for information only. Nothing on this page is investment advice.